Why Statins Are Prescribed in Diabetes Even with LDL <70 mg/dL
Patients with diabetes should receive statin therapy regardless of their baseline LDL cholesterol level because cardiovascular benefit is independent of starting LDL values—the evidence shows mortality reduction is linearly related to the absolute LDL reduction achieved, not the starting point. 1
The Core Principle: Diabetes Itself Defines Risk, Not LDL Level
The fundamental concept here is that diabetes is a cardiovascular disease risk equivalent. The 2025 American Diabetes Association guidelines explicitly state that all people with diabetes aged 40-75 years should be on at least moderate-intensity statin therapy, and those with additional ASCVD risk factors should receive high-intensity statins—independent of baseline LDL cholesterol levels 1.
The Evidence Base
Large meta-analyses of over 18,000 patients with diabetes demonstrated:
- 9% reduction in all-cause mortality per 39 mg/dL LDL reduction
- 13% reduction in vascular mortality per 39 mg/dL LDL reduction
- Critically: These benefits did not depend on baseline LDL cholesterol levels 1
The cardiovascular benefit was linearly related to the absolute LDL cholesterol reduction without a low threshold beyond which there was no benefit observed 1. This means even if someone starts with LDL of 60 mg/dL, lowering it further to 40 mg/dL still provides cardiovascular protection.
Age-Based Treatment Algorithm
Ages 40-75 Years (The Primary Target Group)
- Without additional ASCVD risk factors: Moderate-intensity statin (e.g., atorvastatin 10-20 mg, rosuvastatin 5-10 mg) 1
- With ≥1 additional ASCVD risk factor: High-intensity statin (e.g., atorvastatin 40-80 mg, rosuvastatin 20-40 mg) targeting LDL <70 mg/dL 1
Ages 20-39 Years
- Consider statin therapy if additional ASCVD risk factors are present 1
Ages >75 Years
- Continue statin if already on therapy
- May initiate moderate-intensity statin after risk-benefit discussion 1
Why the LDL Target Matters Even When Starting Low
Even when LDL is already <70 mg/dL, the goal is to:
- Achieve ≥50% reduction from baseline with high-intensity statins in higher-risk patients 1
- Maintain LDL <70 mg/dL as the target for those with additional risk factors 1
This approach recognizes that people with diabetes have:
- Increased prevalence of atherogenic lipid abnormalities beyond just LDL (small dense LDL particles, high triglycerides, low HDL)
- Inherently elevated cardiovascular risk that warrants aggressive prevention
- Proven benefit from statins that extends beyond simple LDL lowering (pleiotropic effects)
Common Pitfalls to Avoid
Don't wait for LDL to be "high": The evidence is clear that baseline LDL level should not determine whether to start a statin in diabetes 1
Don't use low-intensity statins: These are generally not recommended in diabetes—use at least moderate-intensity, and high-intensity for those with additional risk factors 1
Don't defer to "someone else": Clinical inertia and deferral to other providers are major barriers to appropriate statin use (identified in 23.3% and 9.0% of cases respectively) 2
Don't forget that women are undertreated: Female sex is independently associated with lower odds of receiving guideline-recommended statin therapy (OR 0.45) 2
When to Intensify Beyond Statins
If LDL remains ≥70 mg/dL despite maximum tolerated statin therapy in patients aged 40-75 years with multiple ASCVD risk factors, consider adding ezetimibe or a PCSK9 inhibitor 1.
The bottom line: In diabetes, statin therapy is about absolute cardiovascular risk reduction, not just treating an elevated number. The LDL cholesterol level is a treatment target to achieve, not a threshold to determine whether treatment is needed.